KGKyra A. Gelderman

Kyra A. Gelderman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kyra A. Gelderman has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dysregulated complement activation in COVID-19: the role of soluble complement inhibitors

    by Stef van der Meulen, Haiyu Wang, Saskia Nugteren, Frederique Ponchel, Anna H E Roukens, Cilia R Pothast, Mirjam H M Heemskerk, Kyra A Gelderman, Jeroen C J Eikenboom, Bernard M van Den Berg, et al.

    In viral infections, complement activation can contribute to viral clearance, but excessive activation, as observed in severe coronavirus disease 2019 (COVID-19), may drive immunopathology. While much is known about complement-activating factors in COVID-19, insight into the role of endogenous complement inhibitors remains limited. We performed a longitudinal analysis within the BEAT-COVID cohort, comprising hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection admitted to the intensive care unit (ICU) or ward, and age-matched healthy controls. Serum levels of the complement activation marker soluble membrane attack complex (sC5b-9) and soluble inhibitors C1-inhibitor, C4b-binding protein (C4BP), factor H, and factor I were measured by enzyme-linked immunosorbent assay. In vitro endothelial complement sensitivity was assessed by flow cytometry. Soluble inhibitors were also measured in a cohort of patients with long COVID. Patients admitted to the ICU showed elevated sC5b-9 levels compared to patients admitted to the ward and controls, correlating with disease severity, length of hospitalization, and need for mechanical ventilation, but not mortality. Unexpectedly, levels of all soluble complement inhibitors were elevated, particularly in patients admitted to the ICU. Factor H levels positively correlated with sC5b-9. Endothelial cells pre-incubated with serum from patients admitted to the ICU became more susceptible to complement attack. In patients with long COVID, factor H and C4b-binding protein levels remained elevated compared to pre-pandemic healthy controls. Severe COVID-19 is characterized by extensive complement activation despite elevated circulating inhibitor levels, suggesting impaired local complement regulation at the cell surface, potentially amplified by overwhelming systemic activation, rather than inhibitor deficiency.

  • Open Access

    Post-translationally modified proteins bind and activate complement with implications for cellular uptake and autoantibody formation

    by van Den Beukel, L. Zhang, S. van der Meulen, N.V. Borggreven, S. Nugteren, M.C. Brouwer, R.B. Pouw, K.A. Gelderman, A.H. de Ru, G.M.C. Janssen, et al.


  • Open Access

    Autoantibodies and therapeutic antibodies against complement factor H

    by Saskia Nugteren, Haiyu Wang, Cees van Kooten, Kyra A. Gelderman, Leendert A. Trouw


  • Open Access

    Circulating levels of endogenous complement inhibitors correlate inversely with complement consumption in systemic lupus erythematosus

    by Stef van der Meulen, Rory C. Monahan, Kyra A. Gelderman, Cees van Kooten, Y.K. Onno Teng, Tom W.J. Huizinga, Gerda M. Steup‐Beekman, Leendert A. Trouw

    Systemic lupus erythematosus (SLE) is marked by excessive complement activation, contributing to tissue damage. Complement activation can be detected in many organs including the skin, kidney, and brain. The involvement of the central nervous system is particularly relevant to understanding neuropsychiatric SLE (NPSLE), one of the poorest understood manifestations of SLE for which no biomarkers are available. We studied the levels of complement inhibitors in SLE in relation to disease activity and as possible biomarkers to identify NPSLE. Serum levels of complement inhibitors C1‐inhibitor (C1‐INH), C4b‐binding protein (C4BP), Factor I, and Factor H were measured in 345 SLE patients (including 102 with NPSLE) and 108 healthy controls. Compared with controls, SLE patients had higher C1‐INH and C4BP but lower Factor I and H levels. All inhibitors positively correlated with total C3 and C4 levels. While correlating with the SLE Disease Activity Index (SLEDAI), no distinction in inhibitor levels was found between SLE and NPSLE patients. Over time, C1‐INH and Factor H levels normalized, but no significant changes were observed for C4BP and Factor I. In SLE the levels of circulating complement inhibitors are inversely correlated to complement consumption but do not serve as biomarkers for NPSLE.


  • Open Access

    Human anti-C1q autoantibodies bind specifically to solid-phase C1q and enhance phagocytosis but not complement activation

    by Douwe J. Dijkstra, Fleur S. van de Bovenkamp, Leoni Abendstein, Rob Zuijderduijn, Jos Pool, Cynthia S. M. Kramer, Linda M. Slot, Jan W. Drijfhout, Lisanne de Vor, Kyra A. Gelderman, et al.

    Autoantibodies directed against complement component C1q are commonly associated with autoimmune diseases, especially systemic lupus erythematosus. Importantly, these anti-C1q autoantibodies are specific for ligand-bound, solid-phase C1q and do not bind to fluid-phase C1q. In patients with anti-C1q, C1q levels are in the normal range, and the autoantibodies are thus not depleting. To study these human anti-C1q autoantibodies at the molecular level, we isolated C1q-reactive B cells and recombinantly produced nine monoclonal antibodies (mAbs) from four different healthy individuals. The isolated mAbs were of the IgG isotype, contained extensively mutated variable domains, and showed high affinity to the collagen-like region of C1q. The anti-C1q mAbs exclusively bound solid-phase C1q in complex with its natural ligands, including immobilized or antigen-bound IgG, IgM or CRP, and necrotic cells. Competition experiments reveal that at least 2 epitopes, also targeted by anti-C1q antibodies in sera from SLE patients, are recognized. Electron microscopy with hexameric IgG-C1q immune complexes demonstrated that multiple mAbs can interact with a single C1q molecule and identified the region of C1q targeted by these mAbs. The opsonization of immune complexes with anti-C1q greatly enhanced Fc-receptor-mediated phagocytosis but did not increase complement activation. We conclude that human anti-C1q autoantibodies specifically bind neo-epitopes on solid-phase C1q, which results in an increase in Fc-receptor-mediated effector functions that may potentially contribute to autoimmune disease immunopathology.


  • Open Access

    C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia

    by Esther C. W. de Boer, Marit Jalink, Laura Delvasto-Nuñez, Elisabeth M. Meulenbroek, Inge Baas, Susanne R. Janssen, Claudia C. Folman, Kyra A. Gelderman, Diana Wouters, Marije D. Engel, et al.

    Complement-mediated (CM) autoimmune hemolytic anemia (AIHA) is characterized by the destruction of red blood cells (RBCs) by autoantibodies that activate the classical complement pathway. These antibodies also reduce transfusion efficacy via the lysis of donor RBCs. Because C1-inhibitor (C1-INH) is an endogenous regulator of the classical complement pathway, we hypothesized that peritransfusional C1-INH in patients with severe CM-AIHA reduces complement activation and hemolysis, and thus enhances RBC transfusion efficacy. We conducted a prospective, single-center, phase 2, open-label trial (EudraCT2012-003710-13). Patients with confirmed CM-AIHA and indication for the transfusion of 2 RBC units were eligible for inclusion. Four IV C1-INH doses (6000, 3000, 2000, and 1000 U) were administered with 12-hour intervals around RBC transfusion. Serial blood samples were analyzed for hemolytic activity, RBC opsonization, complement activation, and inflammation markers. Ten patients were included in the study. C1-INH administration increased plasma C1-INH antigen and activity, peaking at 48 hours after the first dose and accompanied by a significant reduction of RBC C3d deposition. Hemoglobin levels increased briefly after transfusion but returned to baseline within 48 hours. Overall, markers of hemolysis, inflammation, and complement activation remained unchanged. Five grade 3 and 1 grade 4 adverse event occurred but were considered unrelated to the study medication. In conclusion, peritransfusional C1-INH temporarily reduced complement activation. However, C1-INH failed to halt hemolytic activity in severe transfusion-dependent–CM-AIHA. We cannot exclude that posttransfusional hemolytic activity would have been even higher without C1-INH. The potential of complement inhibition on transfusion efficacy in severe CM-AIHA remains to be determined.